Compare NEON & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | AYTU |
|---|---|---|
| Founded | 1997 | N/A |
| Country | Sweden | United States |
| Employees | 43 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 25.7M |
| IPO Year | 1994 | 2015 |
| Metric | NEON | AYTU |
|---|---|---|
| Price | $1.65 | $2.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 96.7K | 38.8K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,108,000.00 | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $43.34 | $44.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $1.50 | $0.95 |
| 52 Week High | $29.90 | $3.07 |
| Indicator | NEON | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 58.29 |
| Support Level | N/A | $2.14 |
| Resistance Level | $2.04 | $2.72 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 34.44 | 83.78 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.